

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/126945 A1

(43) International Publication Date
06 July 2023 (06.07.2023)

(51) International Patent Classification:

A61K 31/195 (2006.01) *A61K 9/00* (2006.01)
A61K 47/18 (2017.01) *A61P 25/14* (2006.01)
A61K 47/22 (2006.01) *A61P 25/16* (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/IL2023/050001

(22) International Filing Date:

01 January 2023 (01.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/296,019 03 January 2022 (03.01.2022) US

(71) Applicant: **NEURODERM, LTD.** [IL/IL]; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL).

(72) Inventors: **BIRNBERG, Tal**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL). **BEN ELIAHU, Shmuel**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL). **VOSTOKOVA, Natalia**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL). **FINKELSHTEIN BEKER, Danit**; 3 Pekeris Street, Rabin Science Park, 7670212 Rehovot (IL).

(74) Agent: **FISHER, Michal** et al.; FISHER FRIEDMAN IP GROUP, PO BOX 12352, 4673300 Hertzliya Pituach (IL).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE

(57) Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

WO 2023/126945 A1